Previous Close | 0.4000 |
Open | 0.4000 |
Bid | 0.0000 |
Ask | 0.7500 |
Strike | 7.50 |
Expire Date | 2024-08-16 |
Day's Range | 0.4000 - 0.4000 |
Contract Range | N/A |
Volume | |
Open Interest | 21 |
NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the publication of preclinical GD2-SADA data at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting, taking place May 31 through June 4, 2024, in Chicago, IL. T
NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced new interim data from the Phase 2 Trial 201 of naxitamab in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”) in patients with relapsed or refractory hi
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2024 Earnings Call Transcript May 8, 2024 Y-mAbs Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to Y-mAbs Therapeutics Inc. Earnings Conference Call for the First Quarter of 2024. […]